Recent News Releases

• Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive committee members Lee Heeson and Gregory Oakes to leave the company for personal reasons Succession planning ongoing St. Gallen, Switzerland,...

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...

CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion. 05 Oct 2021 Global biotech leader CSL has...

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of...

First orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan Partner Kissei to market TAVNEOS® in Japan, with launch expected as soon as...

CSL has remained agile to stay ahead of the pandemic challenges and has redirected resources to where it can add the most value to address the pandemic challenges. From the time the coronavirus...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis...

CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...

Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership...